Pralmorelin: Research Overview of GHRP-2's INN
A research-framed overview of pralmorelin — the international nonproprietary name behind GHRP-2, why the same peptide carries two labels, and the diagnostic-research strand that sets pralmorelin apart from the rest of the GHRP family.
If you've read about GHRP-2, you've already read about pralmorelin — they're the same peptide under two names. The duplication isn't an accident or a scam; it's what happens when a research-series compound is formally named for clinical development. Pralmorelin is worth its own overview for two reasons: the naming itself trips people up, and pralmorelin carries a diagnostic-research strand that distinguishes it from its GHRP siblings. This is a research-use explainer; pralmorelin is not in our verified-compound catalog, so nothing here is sourcing or dosing advice.
Two names, one peptide
"GHRP-2" is a research-series label — the second entry in the early growth-hormone-releasing peptide family. Pralmorelin is the international nonproprietary name (INN), the formal generic name assigned to a drug candidate as it moves through clinical development. Same molecule, different naming systems: one from the lab series, one from the regulatory and pharmaceutical naming process.
This matters practically. A vendor may list "GHRP-2," "pralmorelin," or "pralmorelin (GHRP-2)" for identical material. Recognizing the synonym prevents you from treating one peptide as two — and prevents marketing from implying a "new" compound when it's a relabeling.
Pralmorelin and GHRP-2 are the same peptide. An INN signals that a compound went far enough into formal development to earn a generic name — it does not, by itself, mean the compound is approved, nor does it change the peptide's biology. Don't let dual naming be spun into a story about novelty or legitimacy. What's in the vial still comes down to the batch and its COA.
What the peptide is
Pralmorelin belongs to the growth-hormone-releasing peptide (GHRP) family — the ghrelin-mimetic secretagogues that imitate ghrelin at the GHS-R1a receptor to drive pituitary growth-hormone release. As an early-generation GHRP, it shares the class signature: effective GH release alongside the non-selective tendency to also nudge cortisol and prolactin.
| Property | Value |
|---|---|
| Research-series name | GHRP-2 |
| INN | Pralmorelin |
| Class | Growth-hormone secretagogue (GHRP / ghrelin mimetic) |
| Primary receptor | Ghrelin receptor (GHS-R1a) |
| Regulatory status (US) | Research compound, not FDA-approved |
How pralmorelin diverges from its closest sibling, GHRP-6, is the subject of our GHRP-2 vs GHRP-6 comparison — the short version is that GHRP-6 carries a stronger appetite-stimulating signal, while pralmorelin is often framed as the more GH-focused of the pair within the same non-selective generation.
The diagnostic-research strand
The reason pralmorelin earns its own discussion rather than living entirely inside a GHRP-2 entry is the line of work treating it as a growth-hormone secretagogue stimulus for diagnostic research — using a controlled GHRP challenge to probe the responsiveness of the pituitary GH axis. This is the kind of mechanistic, provocation-style use that pushed GHRP-2/pralmorelin further into formal characterization than some of its siblings, and it's part of why it acquired an INN at all.
Two cautions keep this honest. First, a peptide being studied as a research probe of the GH axis is a statement about a controlled investigational setting, not an endorsement of general use. Second, the existence of a diagnostic-research strand and an INN does not equal US approval — pralmorelin remains an unapproved research compound here. The underlying biology it probes, pulsatile GH and downstream IGF-1 signaling, is laid out in our GH/IGF-1 axis explainer.
What the research has examined
The pralmorelin / GHRP-2 literature is among the deeper bodies of work in the early GHRP family.
- GH-release pharmacology. Studies characterized the magnitude and kinetics of growth-hormone output, establishing pralmorelin as a potent, well-described secretagogue of its generation.
- Diagnostic provocation. The strand above — using a GHRP challenge to assess GH-axis responsiveness in research settings.
- Off-target profile. As a non-selective GHRP, the accompanying cortisol and prolactin effects are documented and frame how cleanly any GH signal can be interpreted.
Even with a comparatively deep characterization, the gap between "studied as a research probe and investigational candidate" and "an established intervention for general use" remains, and pralmorelin holds no US approval.
How to read pralmorelin claims critically
The same compound-level discipline applies across the secretagogue family.
- Collapse the synonym. Treat "pralmorelin" and "GHRP-2" as one compound. If a listing presents them as distinct or implies the INN confers approval, that's a red flag.
- Keep the pathway straight. Pralmorelin acts on GHS-R1a — the ghrelin door — distinct from the GHRH-analog route covered in our GHRP vs GHRH explainer. Class confusion fuels overstated claims.
- Frame the diagnostic strand precisely. Research-probe use of the GH axis is not a green light for general use, and an INN is not an approval.
- Distrust confident human claims without trials. Specific human outcome statements unbacked by published controlled trials deserve the same skepticism as a purity figure offered without a batch-specific COA.
Where this sits in the broader peptide picture
Pralmorelin sits in the growth-hormone-secretagogue corner of peptide research, alongside its GHRP siblings and the GHRH analogs. For the secretagogue compounds actually in our verified catalog and how they map to research aims, see the peptide reference library and the growth-hormone research goal. For the selective member the non-selective generation is implicitly measured against, our ipamorelin research profile is the natural companion, and the class-wide mechanics live in growth-hormone secretagogue mechanisms. For how any research peptide is made and verified, see how peptides are synthesized and tested.
Bottom line
Pralmorelin is GHRP-2 under its international nonproprietary name — one peptide, two labels, a synonym worth collapsing before you read any claim about it. It's a potent, non-selective early-generation secretagogue acting on the ghrelin receptor, distinguished within its family by a diagnostic-research strand that probes the responsiveness of the GH axis. Read the dual naming as a development artifact rather than a sign of novelty or approval, frame the diagnostic work as investigational, keep the ghrelin and GHRH pathways distinct, and treat it as an active research compound with no validated general role. For verified compounds and where they fit, start at our research goals and buying guides.
For research use only. Not FDA-approved, not for human consumption.
The top-ranked supplier in our 2026 evaluation
ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.
- Cold-chain shipped
- Batch CoA in every box
- 30-day re-test policy
- 98%+ verified purity
Disclosure: Peptide Research Review maintains affiliate relationships with some of the suppliers we reference. Affiliate status has no influence on our research framing or our blinded, third-party lab evaluations. Read our editorial policy and methodology.
Get the full 38-sample purity report by email.
Eight US suppliers, thirty-eight samples, one blinded analytical lab. Every chromatogram, COA, and supplier score — delivered the moment you subscribe.
PDF delivered instantly. No account required. Unsubscribe anytime.
MK-677 (Ibutamoren) Research Overview (2026): Mechanism, Class & How to Read the Literature
A research-framed overview of MK-677 (ibutamoren) — why it is an orally active, non-peptide ghrelin-receptor agonist rather than a peptide, how it signals through GHS-R1a, and how to read its preclinical and clinical literature accurately.
Hexarelin: A Research Overview of the Potent GHRP (2026)
A research-framed overview of hexarelin — the potent hexapeptide growth-hormone secretagogue, how it differs from selective GHRPs like ipamorelin, its distinctive cardiac-receptor research strand, and what the literature does and doesn't establish.
GHRP-2 vs GHRP-6 Research (2026): Two Ghrelin-Mimetics Compared in the Literature
A research-framed comparison of GHRP-2 and GHRP-6 — two peptides in the same ghrelin-mimetic class, what distinguishes them in the literature (appetite signaling, selectivity, cortisol/prolactin discussion), and how to read intra-class differences accurately.